sponsored content
October 12, 2023
At the American Academy of Optometry’s Annual Meeting, Review of Myopia Management’s Editor-in-Chief John Sailer interviewed Dr. Juan Carlos Aragón, CEO of Visioneering Technologies Inc.
At the meeting, VTI shared the one-year data from its PROTECT Trial (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial), which was designed to demonstrate the safety and effectiveness of NaturalVue Multifocal Contact Lenses for myopia progression control in children.
In this interview, Dr. Aragón discusses VTI’s innovative myopia management efforts, the one-year results from its PROTECT Trial, the safety and efficacy of the NaturalVue Multifocal contact lenses, and what the future holds for VTI. Click on the video to watch the full discussion.
Disclaimer: This information may describe uses for this product, i.e., Myopia Progression Control, which have not been approved by the FDA for use in the United States. It is intended for educational purposes only. NaturalVue Multifocal is part of an ongoing randomized clinical trial (RCT) studying its effectiveness for myopia progression control. This information has been reviewed and approved by VTI’s Promotional Review Committee.
In the United States, NaturalVue is FDA-indicated for myopia correction in children with no age or Rx restriction and may be used for myopia management. NaturalVue is also indicated for presbyopia management.
Outside of the U.S. — Canada, Europe, United Kingdom, Hong Kong, Singapore, Malaysia, Australia and New Zealand: NaturalVue is indicated for myopia progression control and for presbyopia management.
